Ozette, a Seattle, Washington-based life sciences startup, today announced that it raised $6 million in seed funding from Madrona Venture Group and the Allen Institute for AI (AI2). Ozette, a spinout founded in 2020 and incubated at AI2, aims to build an immune monitoring platform powered by technologies developed at the Fred Hutch. According to Ansary, Ozette provides a view of single-cell data while automatically delivering results and reproducible experiments, agnostic of instrumentations.a“Think of the Ozette [platform] like an MRI for the immune system,” Ansary explained. Immunai, a company developing a proprietary corpus of immune-centric human tissue analyses, recently emerged from stealth with $20 million in funding. Ozette plans to continue supporting the open-source Cytoverse community, which relies on tooling developed by the company’s team, while developing the immune monitoring platform.